Rebiotix

What Rebiotix does

Rebiotix is a development-stage biotechnology company founded in 2011 that develops human microbiome therapeutics for gastrointestinal diseases, with a primary focus on treating recurrent Clostridioides difficile infection (CDI). The company's core technology is fecal microbiota transplantation (FMT), delivered through a pipeline of standardized, manufactured microbiome-based therapeutic candidates designed to restore healthy gut microbiota. The company is differentiated from traditional FMT approaches by its emphasis on pharmaceutical-grade manufacturing consistency, scalability, and regulatory-grade product development. FMT-based therapies account for approximately 79% of the microbiome therapeutics market in 2025, underscoring the commercial relevance of Rebiotix's chosen modality.

Rebiotix was acquired by Ferring Pharmaceuticals in 2018 and operates as a wholly-owned subsidiary, benefiting from Ferring's capital base, manufacturing expertise, and global pharmaceutical distribution capabilities. The company is based in Roseville, MN (with firmographics listing Rockville as well), with operations including a stool donor screening and sample collection facility supporting microbiome research. The GiveACrapMN donor program recruits and screens healthy donors, compensating them $50 per COVID-19 test and $30 per qualifying donation, building the raw material pipeline for therapeutic development. Rebiotix is led by co-founder Lee Jones (President & CEO), with Erwin Kelen as co-founder.

The business model follows the pharmaceutical pathway: clinical validation through trials, regulatory milestones including FDA designations, and eventual prescription-based product distribution through hospital and specialty pharmacies upon approval. The company is pre-revenue with no commercial products on the market, generating no disclosed revenue. Future revenue will derive from pharmaceutical product sales contingent on regulatory approval. Go-to-market efforts are channeled through scientific publications, clinical trial announcements, medical conferences, and healthcare industry partnerships rather than direct consumer marketing. In August 2024, Rebiotix expanded its pipeline and manufacturing capabilities under Ferring's ownership, signaling continued investment toward potential commercialization.

Name

Rebiotix

Legal name

Rebiotix Inc.

Website

https://rebiotix.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Rebiotix is a clinical-stage biotechnology company developing standardized microbiome therapeutics based on fecal microbiota transplantation to treat recurrent C. difficile infections, operating as a wholly-owned subsidiary of Ferring Pharmaceuticals since 2018.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products (HLAAAFAE)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)

Keywords

• Microbiome therapeutics
• Fecal microbiota transplantation
• Live biotherapeutic products
• Clostridioides difficile treatment
• Human microbiome products

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Rebiotix is developing microbiome therapeutic products that will generate revenue through pharmaceutical product sales upon regulatory approval. The company is expanding manufacturing capabilities to support eventual commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Rebiotix is a clinical-stage biotechnology company developing standardized, manufactured microbiome therapeutics based on fecal microbiota transplantation (FMT). Its lead focus is the treatment and prevention of recurrent Clostridioides difficile infection, with a broader pipeline aimed at other microbiome-related gastrointestinal and systemic diseases. The company supports development with an in-house stool donor screening and collection program.

Product overview

No product or service information available for Rebiotix in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

• Microbiome Therapeutic Pipeline (FMT-based candidates for recurrent CDI) A clinical-stage pipeline of standardized, manufactured fecal microbiota transplantation (FMT)-based therapeutic candidates intended for the treatment and prevention of recurrent Clostridioides difficile infection and other microbiome-related diseases, to be prescribed by healthcare providers upon regulatory approval.
• GiveACrapMN Stool Donor Program A stool donor screening and collection program supporting Rebiotix's microbiome therapeutics development for C. difficile research. Located at 2660 Patton Road, Roseville, MN, the program recruits, screens, and compensates donors to supply material for FMT-based therapeutic development.

Quantifiable outcome

• FMT achieves high clinical success rates in treating recurrent CDI, with the fecal microbiota transplantation segment accounting for approximately 79% of the microbiome therapeutics market in 2025

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Direct peers

• Seres Therapeutics: Seres Therapeutics developed Vowst, the first orally administered microbiome therapeutic approved by the FDA for prevention of recurrent CDI in 2023. It is the most direct competitor to Rebiotix/Ferring's Rebyota, targeting the same recurrent CDI patient population with a defined-consortium microbiome approach.
• MaaT Pharma: MaaT Pharma is a European clinical-stage microbiome therapeutics company developing standardized, pooled-donor FMT-like products (MaaT013, MaaT033) for GI diseases including CDI and graft-versus-host disease. It is a direct peer operating the same standardized FMT manufacturing model as Rebiotix.
• Vedanta Biosciences: Vedanta Biosciences is developing defined bacterial consortium microbiome therapeutics, including programs in CDI and other GI indications. It is a clinical-stage direct peer pursuing a more synthetic, defined-strain approach to microbiome therapeutics in overlapping indications.

Emerging players

• Assembly Biosciences: Assembly Biosciences has pivoted portions of its pipeline into microbiome-based approaches for serious diseases. It is an emerging clinical-stage player with overlap in microbiome therapeutic modalities targeting similar GI and immunological indications.
• Siolta Therapeutics: Siolta Therapeutics is a clinical-stage company developing defined-consortium live biotherapeutic products for inflammatory diseases including ulcerative colitis and asthma. It is an emerging peer in standardized microbiome therapeutics targeting overlapping inflammatory indications.
• Second Genome: Second Genome is a clinical-stage company using microbiome-based drug discovery to identify novel therapeutics for serious diseases. It is an emerging peer applying microbiome science to drug development in overlapping GI and metabolic indications.
• 4D pharma: 4D pharma was a UK-based clinical-stage microbiome therapeutics company developing live biotherapeutics for cancer and GI disease. It is an emerging peer in the broader live-biotherapeutic category overlapping Rebiotix's therapeutic areas, though it has undergone significant restructuring.
• Finch Therapeutics: Finch Therapeutics developed Finch 301 (CP101), an FMT-based oral microbiome therapeutic for recurrent CDI, before restructuring. It remains a relevant emerging peer in FMT-based microbiome therapeutics with comparable technology and target indication to Rebiotix.
• Evelo Biosciences: Evelo Biosciences is developing oral, single-strain microbiome therapeutics for inflammatory diseases. It represents an emerging-player approach using defined microbial strains rather than full FMT, competing in adjacent indications to Rebiotix's pipeline expansion plans.

Broad incumbents

• Ferring Pharmaceuticals: Ferring Pharmaceuticals is Rebiotix's parent company and a global specialty pharma with deep GI and reproductive health franchises. It is included as a peer because it owns and commercializes Rebyota (developed by Rebiotix), making it the commercial channel and strategic owner of Rebiotix's lead asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Rebiotix
• Facebookfacebook.com/Rebiotix
• LinkedInlinkedin.com/company/rebiotix

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rebiotix